Suchergebnisse

Candidate Pilot IMI projects (eTOX, ND4BB-TRANSLOCATION, ReSOLUTE, Aetionomy, OncoTrack and OPENPhacts) were initially identified based upon a long list highlighted in the DoA and through the FAIRplus partner network. Summaries of the activities and data sets available within these candidate Pilot IMI projects were collected via a survey tool, and further information was presented at the FAIRplus kick-off event by project owners. Following review, WP1 prioritized 4 IMI projects as Pilots, (eTOX, ND4BB-TRANSLOCATION, ReSOLUTE and OncoTrack). The prioritized Pilots were ratified by the General Assembly and formally selected. Each project was then assigned a key FAIRplus contact person, who worked with the data owners to identify, prioritise and release suitable data sets to the FAIRplus consortium, Squads and WP2 / 3 members. As of 30.06.2019, data sets have been released from eTOX, ND4BB-TRANSLOCATION and ReSOLUTE. OncoTrack is on course to release data in July 2019. ; This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA companies.

Creating selection criteria and guidelines, to aid identification of IMI datasets with the potential to generate high societal impact upon FAIRification, is an important goal of FAIRplus. This deliverable report describes the process put in place to identify, evaluate and select projects. Two thirds of projects to be addressed by FAIRplus will cover societal priorities of H2020, namely; 1) promoting healthy ageing[1]; 2) addressing chronic diseases; 3) neurodegenerative diseases and 4) emergence of antibiotic resistance. In addition, we have identified cross-cutting projects "Cross" which provide tools such as cell lines, biomarkers and animal models, which enable research progression in the primary priority areas. In the first period, some 25 projects have been identified based on the application of the criteria and discussions are ongoing with these consortia representatives in order to provide a steady flow of datasets into FAIRplus. [1] see http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing ; This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA companies.

© The Author(s), 2012. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Nature Genetics 44 (2012): 121-126, doi:10.1038/ng.1054. ; To make full use of research data, the bioscience community needs to adopt technologies and reward mechanisms that support interoperability and promote the growth of an open 'data commoning' culture. Here we describe the prerequisites for data commoning and present an established and growing ecosystem of solutions using the shared 'Investigation-Study-Assay' framework to support that vision. ; The authors also acknowledge the following funding sources in particular: UK Biotechnology and Biological Sciences Research Council (BBSRC) BB/I000771/1 to S.-A.S. and A.T.; UK BBSRC BB/I025840/1 to S.-A.S.; UK BBSRC BB/I000917/1 to D.F.; EU CarcinoGENOMICS (PL037712) to J.K.; US National Institutes of Health (NIH) 1RC2CA148222-01 to W.H. and the HSCI; US MIRADA LTERS DEB-0717390 and Alfred P. Sloan Foundation (ICoMM) to L.A.-Z.; Swiss Federal Government through the Federal Office of Education and Science (FOES) to L.B. and I.X.; EU Innovative Medicines Initiative (IMI) Open PHACTS 115191 to C.T.E.; US Department of Energy (DOE) DE-AC02- 06CH11357 and Arthur P. Sloan Foundation (2011- 6-05) to J.G.; UK BBSRC SysMO-DB2 BB/I004637/1 and BBG0102181 to C.G.; UK BBSRC BB/I000933/1 to C.S. and J.L.G.; UK MRC UD99999906 to J.L.G.; US NIH R21 MH087336 (National Institute of Mental Health) and R00 GM079953 (National Institute of General Medical Science) to A.L.; NIH U54 HG006097 to J.C. and C.E.S.; Australian government through the National Collaborative Research Infrastructure Strategy (NCRIS); BIRN U24-RR025736 and BioScholar RO1-GM083871 to G.B. and the 2009 Super Science initiative to C.A.S.